Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis

International Journal of Antimicrobial Agents

Volumn 45, Issue 3, 2015, Pages 268-277

  Bhattacharjee, Amrita ^a   Majumder, Saikat ^a   Majumdar, Suchandra Bhattacharyya ^a   Choudhuri, Soumitra Kumar ^b   Roy, Syamal ^c   Majumdar, Subrata ^a  

^a BOSE INSTITUTE   (India)

^b CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

^c INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

ABC transporter; Antimony; Drug resistance; Immunomodulator; Macrophages

Indexed keywords

ABC TRANSPORTER; ANTIMONY GLUCONATE; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCYRRHIZIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTIPROTOZOAL AGENT; ENZYME INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG POTENTIATION; DRUG TRANSPORT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOST CELL; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; LIVER CELL; MOUSE; NONHUMAN; PARASITE LOAD; PERITONEUM MACROPHAGE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RNA EXTRACTION; SPLEEN CELL; TH1 CELL; VISCERAL LEISHMANIASIS; WESTERN BLOTTING; ACTIVE TRANSPORT; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG RESISTANCE; ISOLATION AND PURIFICATION; LEISHMANIA; LEISHMANIASIS, VISCERAL; LIVER; PARASITOLOGY; PROCEDURES; SPLEEN; TREATMENT OUTCOME;

ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTIPROTOZOAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GLYCYRRHIZIC ACID; LEISHMANIA; LEISHMANIASIS, VISCERAL; LIVER; MICE, INBRED BALB C; PARASITE LOAD; SPLEEN; TREATMENT OUTCOME;

EID: 84923689406     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.10.023     Document Type: Article

References (30)

1. World Health Organization Leishmaniasis WHO fact sheet no. 375 2014 WHO Geneva, Switzerland
2. H.W. Murray, J.D. Berman, C.R. Davies, and N.G. Saravia Advances in leishmaniasis Lancet 366 2005 1561 1577
3. S. Sundar, D.K. More, M.K. Singh, V.P. Singh, S. Sharma, and A. Makharia Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic Clin Infect Dis 31 2000 1104 1107
4. A.K. Haldar, P. Sen, and S. Roy Use of antimony in the treatment of leishmaniasis: current status and future directions Mol Biol Int 2011 2011 571242
5. M. Ouellette, D. Legare, A. Haimeur, K. Grondin, G. Roy, and C. Brochu ABC transporters in Leishmania and their role in drug resistance Drug Resist Updat 1 1998 43 48
6. J. Mookerjee Basu, A. Mookerjee, R. Banerjee, M. Saha, S. Singh, and K. Naskar Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection Antimicrob Agents Chemother 52 2008 1080 1093
7. A.C. Abreu, A.J. McBain, and M. Simoes Plants as sources of new antimicrobials and resistance-modifying agents Nat Prod Rep 29 2012 1007 1021
8. S.K. Martin, A.M. Oduola, and W.K. Milhous Reversal of chloroquine resistance in Plasmodium falciparum by verapamil Science 235 1987 899 901
9. X.Y. Wan, M. Luo, X.D. Li, and P. He Hepatoprotective and anti-hepatocarcinogenic effects of glycyrrhizin and matrine Chem Biol Interact 181 2009 15 19
10. R. Khan, A.Q. Khan, A. Lateef, M.U. Rehman, M. Tahir, and F. Ali Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats PLoS One 8 2013 e56020
11. N. Yoshida, T. Takada, Y. Yamamura, I. Adachi, H. Suzuki, and J. Kawakami Inhibitory effects of terpenoids on multidrug resistance-associated protein 2- and breast cancer resistance protein-mediated transport Drug Metab Dispos 36 2008 1206 1211
12. Majumdar S. A process for preparing pure glycyrrhizic acid from licorice. Patent application no. 771/KOL/2005. Govt. of India, International classification no. A61K/31/00, 2006.
13. L. Das, N. Datta, S. Bandyopadhyay, and P.K. Das Successful therapy of lethal murine visceral leishmaniasis with cystatin involves up-regulation of nitric oxide and a favorable T cell response J Immunol 166 2001 4020 4028
14. F.C. Odds Synergy, antagonism, and what the chequerboard puts between them J Antimicrob Chemother 52 2003 1
15. Y. Yamamura, T. Santa, H. Kotaki, K. Uchino, Y. Sawada, and T. Iga Administration-route dependency of absorption of glycyrrhizin in rats: intraperitoneal administration dramatically enhanced bioavailability Biol Pharm Bull 18 1995 337 341
16. W.L. Roberts, and P.M. Rainey Antimony quantification in Leishmania by electrothermal atomic absorption spectroscopy Anal Biochem 211 1993 1 6
17. S. Ghosh, S. Bhattacharyya, M. Sirkar, G.S. Sa, T. Das, and D. Majumdar Leishmania donovani suppresses activated protein 1 and NF-κB activation in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase Infect Immun 70 2002 6828 6838
18. S.J. Green, S. Mellouk, S.L. Hoffman, M.S. Meltzer, and C.A. Nacy Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from l-arginine by macrophages and hepatocytes Immunol Lett 25 1990 15 19
19. S.L. Croft, R.N. Davidson, and E.A. Thornton Liposomal amphotericin B in the treatment of visceral leishmaniasis J Antimicrob Chemother 28 1991 111 118
20. T.P. Dorlo, M. Balasegaram, J.H. Beijnen, and P.J. de Vries Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis J Antimicrob Chemother 67 2012 2576 2597
21. A.K. Haldar, S. Banerjee, K. Naskar, D. Kalita, N.S. Islam, and S. Roy Sub-optimal dose of sodium antimony gluconate (SAG)-diperoxovanadate combination clears organ parasites from BALB/c mice infected with antimony resistant Leishmania donovani by expanding antileishmanial T-cell repertoire and increasing IFN-gamma to IL-10 ratio Exp Parasitol 122 2009 145 154
22. C. Pal, M. Raha, A. Basu, K.C. Roy, A. Gupta, and M. Ghosh Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters Antimicrob Agents Chemother 46 2002 259 261
23. H. Lage ABC-transporters: implications on drug resistance from microorganisms to human cancers Int J Antimicrob Agents 22 2003 188 199
24. S.A. Peel The ABC transporter genes of Plasmodium falciparum and drug resistance Drug Resist Updat 4 2001 66 74
25. B. Papadopoulou, G. Roy, S. Dey, B.P. Rosen, and M. Ouellette Contribution of the Leishmania P-glycoprotein-related gene ltpgpA to oxyanion resistance J Biol Chem 269 1994 11980 11986
26. L. Vernhet, A. Courtois, N. Allain, L. Payen, J.P. Anger, and A. Guillouzo Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells FEBS Lett 443 1999 321 325
27. K. Seifert, P. Escobar, and S.L. Croft In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent J Antimicrob Chemother 65 2010 508 511
28. M.E. Ibrahim, M. Hag-Ali, A.M. el-Hassan, T.G. Theander, and A. Kharazmi Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing Parasitol Res 80 1994 569 574
29. G.S. Nabors, and J.P. Farrell Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses Infect Immun 62 1994 5498 5504
30. H.W. Murray, C. Montelibano, R. Peterson, and J.P. Sypek Interleukin-12 regulates the response to chemotherapy in experimental visceral leishmaniasis J Infect Dis 182 2000 1497 1502